MEDI4736+tremelimumab

BIOLOGICAL2 trials

Sponsors

MedImmune LLC, AstraZeneca

Conditions

Gastric or Gastroesophageal Junction AdenocarcinomaSquamous Cell Carcinoma of the Head and Neck

Phase 1

A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

CompletedNCT02340975

MedImmune LLCGastric or Gastroesophageal Junction Adenocarcinoma

Start: 2015-03-31End: 2019-04-29Updated: 2020-06-09

Phase 3

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer

CompletedNCT02551159

AstraZenecaSquamous Cell Carcinoma of the Head and Neck

Start: 2015-10-15End: 2021-05-21Updated: 2021-10-13

Related Papers

Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.

2024-03-025 citations

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

Journal of Clinical Oncology2022-12-06140 citations

591 Immunogenicity of durvalumab: analysis of pooled pan-tumor data

Regular and Young Investigator Award Abstracts2022-11-01

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.

2019-01-1436 citations

Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.

Journal of Clinical Oncology2018-05-2014 citations

Early reduction in circulating tumor DNA (ctDNA) and survival in gastric cancer patients (pts) treated with durvalumab (D), tremelimumab (T), or durvalumab in combination with tremelimumab (D+T).

Journal of Clinical Oncology2018-05-203 citations

A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.

Journal of Clinical Oncology2016-05-2032 citations